Srinath Sundararajan
Overview
Explore the profile of Srinath Sundararajan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
163
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rokkam V, Kutti Sridharan G, Thai T, Amaraneni A, Sundararajan S
Am J Ther
. 2023 Jun;
30(3):e298-e300.
PMID: 37278712
No abstract available.
2.
Chaus F, Craig M, Bracamonte E, Sundararajan S, Lee B
J Endourol Case Rep
. 2020 Aug;
5(4):151-153.
PMID: 32775650
Primary malignant melanoma (PMM) of the urinary tract is a rare entity, with only 28 cases reported in the literature. We present an interesting case of a 27-year-old Caucasian woman,...
3.
Myrdal C, Sundararajan S, Curiel-Lewandrowski C
Case Rep Dermatol
. 2020 Aug;
12(2):119-123.
PMID: 32774246
Hypertrophic lichen planus (HLP) may not have the typical histological findings of lichen planus and often mimics squamous cell carcinoma (SCC). Distinguishing between the two can pose a diagnostic challenge....
4.
Myrdal C, Sundararajan S
Case Rep Oncol Med
. 2020 Jul;
2020:4392562.
PMID: 32670650
Little is known about the optimal sequencing of targeted therapy and immunotherapy in the treatment of patients with BRAF-mutated metastatic melanoma. BRAF/MEK inhibition often has the benefit of rapid disease...
5.
Gravbrot N, Scherer K, Sundararajan S
Case Rep Oncol Med
. 2019 Dec;
2019:5490707.
PMID: 31885974
Background: Immune checkpoint inhibitors are novel therapies with indications for treating several solid cancers. They are associated with immune-related adverse events, which are generally well tolerated. Though rare, severe side...
6.
Gravbrot N, Sundararajan S
Case Rep Oncol Med
. 2019 Nov;
2019:3051945.
PMID: 31687241
Encorafenib/binimetinib is a new combination BRAF/MEK inhibitor used in the treatment of advanced or metastatic BRAFV600-mutant melanoma. Though generally tolerated well, mild to moderate aminotransferase elevations are common. However, significant...
7.
Gravbrot N, Gilbert-Gard K, Mehta P, Ghotmi Y, Banerjee M, Mazis C, et al.
Antibodies (Basel)
. 2019 Oct;
8(4).
PMID: 31640266
Recently, modulation of immune checkpoints has risen to prominence as a means to treat a number of solid malignancies, given the durable response seen in many patients and improved side...
8.
Famoso J, Lemole G, Sundararajan S, Stea B
J Natl Compr Canc Netw
. 2019 Oct;
17(10):1148-1153.
PMID: 31590158
Primary melanoma of the pineal gland is a rare disease entity with an overall poor prognosis. Limited data exist to appropriately guide treatment decisions. Historical case reports have showed some...
9.
Karimkhani C, Reddy B, Dellavalle R, Sundararajan S
BMJ
. 2017 Dec;
359:j5174.
PMID: 29191943
No abstract available.
10.
Abbosh P, Sundararajan S, Millis S, Hauben A, Reddy S, Geynisman D, et al.
Eur Urol Focus
. 2017 Jul;
4(6):969-971.
PMID: 28753842
Metastatic chromophobe renal cell cancer (chRCC) is a rare subtype of RCC with no standard treatment. We performed molecular profiling of 12 chRCC cases to identify alterations predictive of response...